Evidence map›Paper›PMID 41326303›Full record

ArticleThe journal of prevention of Alzheimer's disease2025

Towards an AI biomedical scientist: Accelerating discoveries in neurodegenerative disease.

Kaleigh F Roberts, Eric C Landsness, Justin Reese, Donald Elbert, Gabrielle Strobel, Elizabeth Wu, Yixin Chen, Albert Lai, Zachary B Abrams, Mingfang Zhu and 25 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of prevention of Alzheimer's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Kaleigh F RobertsDepartment of Pathology & Immunology, Washington University, St. Louis, MO, USA; Consortium for Biomedical Research and Artificial Intelligence in Neurodegeneration (C-brAIn).
Eric C LandsnessDepartment of Neurology, Washington University, St. Louis, MO, USA; Consortium for Biomedical Research and Artificial Intelligence in Neurodegeneration (C-brAIn).
Justin ReeseEnvironmental Genomics and Systems Biology Division, Lawrence Berkeley National Laboratory, Berkeley, CA, USA; Consortium for Biomedical Research and Artificial Intelligence in Neurodegeneration (C-brAIn).
Donald ElbertDepartment of Neurology, University of Washington, Seattle, WA, USA; Consortium for Biomedical Research and Artificial Intelligence in Neurodegeneration (C-brAIn).
Gabrielle StrobelAlzforum Foundation Inc., MA, USA; Consortium for Biomedical Research and Artificial Intelligence in Neurodegeneration (C-brAIn).
Elizabeth WuAlzforum Foundation Inc., MA, USA; Consortium for Biomedical Research and Artificial Intelligence in Neurodegeneration (C-brAIn).
Yixin ChenDepartment of Computer Science & Engineering, Washington University, St. Louis, MO, USA; Consortium for Biomedical Research and Artificial Intelligence in Neurodegeneration (C-brAIn).
Albert LaiDepartment of Computer Science & Engineering, Washington University, St. Louis, MO, USA; Institute for Informatics, Data Science and Biostatistics (I2DB), Washington University, St. Louis, MO, USA.
Zachary B AbramsInstitute for Informatics, Data Science and Biostatistics (I2DB), Washington University, St. Louis, MO, USA; Consortium for Biomedical Research and Artificial Intelligence in Neurodegeneration (C-brAIn).
Mingfang ZhuDepartment of Computer Science & Engineering, Washington University, St. Louis, MO, USA.
Justin MelendezDepartment of Neurology, Washington University, St. Louis, MO, USA; Tracy Family SILQ Center, Washington University, St. Louis, MO, USA; Consortium for Biomedical Research and Artificial Intelligence in Neurodegeneration (C-brAIn).
Srinivas KoutarapuDepartment of Neurology, Washington University, St. Louis, MO, USA; Consortium for Biomedical Research and Artificial Intelligence in Neurodegeneration (C-brAIn).
Sihui SongDepartment of Neurology, Washington University, St. Louis, MO, USA; Consortium for Biomedical Research and Artificial Intelligence in Neurodegeneration (C-brAIn).
Yun ChenDepartment of Neurology, Washington University, St. Louis, MO, USA; Consortium for Biomedical Research and Artificial Intelligence in Neurodegeneration (C-brAIn).
Robert LazarBooz Allen Hamilton.
Payam BarnaghiDepartment of Brain Sciences, Imperial College London, London, England United Kingdom.
John F CraryDepartment of Pathology, Nash Family Department of Neuroscience, Department of Artificial Intelligence & Human Health, Neuropathology Brain Bank & Research CoRE, Ronald M. Loeb Center for Alzheimer's Disease, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, NY, NY, USA.
Sergio Pablo SardiSanofi, Cambridge, MA, USA; Consortium for Biomedical Research and Artificial Intelligence in Neurodegeneration (C-brAIn).
Marc D VossSanofi, Cambridge, MA, USA.
Rajaraman KrishnanSanofi, Cambridge, MA, USA.
Joel W SchwartzBristol Myers Squibb, Cambridge, MA, USA.
Ron MallonDepartment of Philosophy, Washington University, St. Louis, MO, USA; Consortium for Biomedical Research and Artificial Intelligence in Neurodegeneration (C-brAIn).
Gustavo A Jimenez-MaggioraAlzheimer's Therapeutic Research Institute, Keck School of Medicine of University of Southern California, San Diego, CA, USA; Consortium for Biomedical Research and Artificial Intelligence in Neurodegeneration (C-brAIn).
Chenguang WangDepartment of Computer Science and Engineering, University of California Santa Cruz, CA, USA; Consortium for Biomedical Research and Artificial Intelligence in Neurodegeneration (C-brAIn).
Thomas SandmannDenali Therapeutics Inc., South San Francisco, CA, USA; Consortium for Biomedical Research and Artificial Intelligence in Neurodegeneration (C-brAIn).
Niranjan BoseAlzheimer's Disease Data Initiative, USA; Sage Bionetworks, USA.
Mukta PhatakThe 10,000 Brains Project, USA; Consortium for Biomedical Research and Artificial Intelligence in Neurodegeneration (C-brAIn).
Gayle WittenbergJohnson & Johnson, USA.
Yannis G KevrekidisDepartment of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, USA; Consortium for Biomedical Research and Artificial Intelligence in Neurodegeneration (C-brAIn).
Cassie S MitchellDepartment of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, USA.
Ludovico MitchenerFutureHouse, USA.
Towfique RajDepartment of Neuroscience, Icahn School of Medicine at Mount Sinai, NY, NY, USA.
Luca FoschiniSage Bionetworks, USA; Consortium for Biomedical Research and Artificial Intelligence in Neurodegeneration (C-brAIn).
Gregory J MooreGates Ventures, USA; Consortium for Biomedical Research and Artificial Intelligence in Neurodegeneration (C-brAIn).
Randall J BatemanDepartment of Neurology, Washington University, St. Louis, MO, USA; Tracy Family SILQ Center, Washington University, St. Louis, MO, USA; Consortium for Biomedical Research and Artificial Intelligence in Neurodegeneration (C-brAIn). Electronic address: batemanr@wustl.edu.

Funding

Regulatory and Human Study Operations (RHSO) Core CU19AG065169 · NIA · UNIVERSITY OF ARIZONA · PI BARNES, CAROL A. · 2021 to 2025
$59.8M
Research Education ComponentP30AG066514 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Fanny M Elahi · 2020 to 2026
$31.0M
Torpor for cerebroprotectionR01NS133365 · NINDS · WASHINGTON UNIVERSITY · PI Eric C Landsness · 2023 to 2026
$1.9M
Integrative predictive medicine to identify disease causes, develop cures, and optimize patient careR35GM152245 · NIGMS · GEORGIA INSTITUTE OF TECHNOLOGY · PI Cassie S Mitchell · 2024 to 2026
$1.1M
NIA NIH HHS P30 AG066514NIA NIH HHS U19 AG065169NIGMS NIH HHS R35 GM152245NINDS NIH HHS R01 NS133365
6 · The paper itself

Abstract

Despite major advances in Alzheimer's disease and related diseases (ADRD) research, the translation of discoveries into impactful clinical interventions remains slow. Overwhelming data complexity, fragmented knowledge, and prolonged research cycles hinder progress in understanding and treating neurodegenerative diseases. Artificial intelligence (AI) offers a promising path forward, particularly when developed as a scientist-in-the-loop system that collaborates with researchers throughout the scientific discovery process. This paper introduces the concept of an AI Biomedical Scientist, an intelligent platform designed to support literature synthesis, hypothesis generation, experimental design, and data interpretation. This platform aims to function as a holistic scientific partner, integrating diverse biomedical data and expert reasoning to accelerate discovery. We review commercial and academic efforts and introduce targeted Minimum Viable Products (MVPs) needed for general biomedical research lab utilization of AI, such as robust and accurate tools for literature and data analysis, negative data models, and virtual peer review, with a longer-term vision of foundation models trained directly on biomedical datasets. In AD and neurodegeneration research, such tools are anticipated to deliver efficiency gains ranging from modest improvements in specific research tasks to potential multi-fold accelerations in discovery workflows as systems mature and scale. This review examines the technical foundations, challenges, and anticipated impacts of AI and aims to inform and engage researchers in utilizing these systems to transform biomedical discovery, starting with AD and extending to other complex conditions.

Indexed as

Alzheimer's diseaseArtificial intelligenceBiomedical AILarge language modelMultimodal datasets

Identifiers

PMID41326303
PMCPMC12811770

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.